Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

Next Previous
Trial Profile

A Multicenter, Randomized, Open-label, Controlled Trial To Assess The Safety And Tolerability Of Lucinactant For Inhalation In Preterm Neonates 26 to 28 Weeks PMA

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sinapultide (Primary)
  • Indications Neonatal respiratory distress syndrome
  • Focus Adverse reactions
  • Sponsors Windtree Therapeutics

Most Recent Events

  • 09 May 2019 According to a Windtree Therapeutics media release, new post-hoc, pooled analysis of two randomized, controlled phase 2 studies (NCT02528318 and NCT02636868) of premature infants with respiratory distress syndrome, were presented at the Pediatric Academic Societies (PAS) Meeting (2019).
  • 09 May 2019 Results of new post-hoc, pooled analysis of two randomized, controlled phase 2 studies (NCT02528318 and NCT02636868) of premature infants with respiratory distress syndrome, presented in a Windtree Therapeutics media release.
  • 28 Dec 2017 According to a Windtree Therapeutics media release, updated results of this trial will be discussed in conference call and live webcast on January 4, 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top